Stockreport

DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

DURECT Corporation  (DRRX) 
Last durect corporation earnings: 3/3 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: durect.com/investors
PDF CUPERTINO, Calif., July 22, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. grant [Read more]